Aier Eye Hospital Group Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Aier Eye Hospital Group de 15.3% y 13.3% por año respectivamente. Se prevé que el BPA crezca en un 14.9% al año. Se espera que la rentabilidad financiera sea de 18.2% en 3 años.

Información clave

15.3%

Tasa de crecimiento de los beneficios

14.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	23.0%
Tasa de crecimiento de los ingresos	13.3%
Rentabilidad financiera futura	18.2%
Cobertura de analistas	Good
Última actualización	13 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Aier Eye Hospital Group Co., Ltd. (SZSE:300015) Fell Short of Analyst Expectations: Here's What You Need To Know

Apr 28

Recent updates

Aier Eye Hospital Group (SZSE:300015) Has A Rock Solid Balance Sheet

Nov 16

Is Now The Time To Put Aier Eye Hospital Group (SZSE:300015) On Your Watchlist?

Oct 08

Insufficient Growth At Aier Eye Hospital Group Co., Ltd. (SZSE:300015) Hampers Share Price

Sep 09

Aier Eye Hospital Group (SZSE:300015) Has A Rock Solid Balance Sheet

Jul 28

Shareholders Are Optimistic That Aier Eye Hospital Group (SZSE:300015) Will Multiply In Value

Jul 12

Aier Eye Hospital Group Co., Ltd.'s (SZSE:300015) Business Is Yet to Catch Up With Its Share Price

Jun 05

Statutory Profit Doesn't Reflect How Good Aier Eye Hospital Group's (SZSE:300015) Earnings Are

May 02

Aier Eye Hospital Group Co., Ltd. (SZSE:300015) Fell Short of Analyst Expectations: Here's What You Need To Know

Apr 28

Calculating The Intrinsic Value Of Aier Eye Hospital Group Co., Ltd. (SZSE:300015)

Apr 02

Many Would Be Envious Of Aier Eye Hospital Group's (SZSE:300015) Excellent Returns On Capital

Mar 15

Aier Eye Hospital Group Co., Ltd.'s (SZSE:300015) Shares May Have Run Too Fast Too Soon

Feb 29

Previsiones de crecimiento de beneficios e ingresos

SZSE:300015 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	27,575	5,110	5,525	6,987	19
12/31/2025	24,444	4,406	4,618	5,863	21
12/31/2024	21,254	3,814	5,080	5,732	16
9/30/2024	20,621	3,629	2,852	4,596	N/A
6/30/2024	20,661	3,696	3,533	5,346	N/A
3/31/2024	20,543	3,477	3,862	5,510	N/A
12/31/2023	20,367	3,359	4,412	5,872	N/A
9/30/2023	19,106	3,348	4,446	6,063	N/A
6/30/2023	18,254	2,945	4,139	5,544	N/A
3/31/2023	16,962	2,695	3,764	5,110	N/A
1/1/2023	16,110	2,524	3,102	4,491	N/A
9/30/2022	16,456	2,677	3,426	4,840	N/A
6/30/2022	15,760	2,499	3,067	4,488	N/A
3/31/2022	15,658	2,450	2,869	4,376	N/A
1/1/2022	15,001	2,323	2,590	4,084	N/A
9/30/2021	14,943	2,181	2,666	4,037	N/A
6/30/2021	15,096	2,163	3,263	4,586	N/A
3/31/2021	13,782	2,128	3,017	4,095	N/A
12/31/2020	11,912	1,724	2,450	3,344	N/A
9/30/2020	10,824	1,694	2,122	2,778	N/A
6/30/2020	9,405	1,360	1,112	1,751	N/A
3/31/2020	9,387	1,160	983	1,637	N/A
12/31/2019	9,990	1,379	1,333	2,078	N/A
9/30/2019	9,616	1,345	1,218	2,022	N/A
6/30/2019	8,978	1,195	903	1,619	N/A
3/31/2019	8,506	1,091	692	1,536	N/A
12/31/2018	8,009	1,009	589	1,400	N/A
9/30/2018	7,705	1,005	825	1,802	N/A
6/30/2018	7,153	890	N/A	1,690	N/A
3/31/2018	6,512	803	N/A	1,466	N/A
12/31/2017	5,963	743	N/A	1,330	N/A
9/30/2017	5,300	721	N/A	992	N/A
6/30/2017	4,671	646	N/A	873	N/A
3/31/2017	4,283	594	N/A	798	N/A
12/31/2016	4,000	557	N/A	775	N/A
9/30/2016	3,807	538	N/A	624	N/A
6/30/2016	3,631	499	N/A	630	N/A
3/31/2016	3,429	459	N/A	537	N/A
12/31/2015	3,166	428	N/A	522	N/A
9/30/2015	3,006	413	N/A	479	N/A
6/30/2015	2,740	367	N/A	480	N/A
3/31/2015	2,535	331	N/A	484	N/A
12/31/2014	2,402	309	N/A	454	N/A
9/30/2014	2,316	296	N/A	486	N/A
6/30/2014	2,200	266	N/A	428	N/A
3/31/2014	2,091	240	N/A	438	N/A
12/31/2013	1,985	223	N/A	413	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (15.3% al año) de 300015 es superior a la tasa de ahorro (2.8%).

Beneficios vs. Mercado: Se prevé que los beneficios (15.3% al año) de 300015 crezcan menos que el mercado CN (26.2% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 300015 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (13.3% al año) de 300015 crezcan más despacio que el mercado de CN (13.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 13.3% al año) de 300015 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 300015 sea baja dentro de 3 años (18.2%).

Aier Eye Hospital Group Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 9.0% to CN¥14.78

Price target decreased by 9.4% to CN¥13.01

Price target decreased by 7.1% to CN¥14.83

Consensus EPS estimates fall by 10%

Aier Eye Hospital Group Co., Ltd. (SZSE:300015) Fell Short of Analyst Expectations: Here's What You Need To Know

Price target decreased by 8.3% to CN¥21.32

Recent updates

Now 23% undervalued

Aier Eye Hospital Group (SZSE:300015) Has A Rock Solid Balance Sheet

Price target increased by 9.0% to CN¥14.78

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 27%

Is Now The Time To Put Aier Eye Hospital Group (SZSE:300015) On Your Watchlist?

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Insufficient Growth At Aier Eye Hospital Group Co., Ltd. (SZSE:300015) Hampers Share Price

Price target decreased by 9.4% to CN¥13.01

Price target decreased by 7.1% to CN¥14.83

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Aier Eye Hospital Group (SZSE:300015) Has A Rock Solid Balance Sheet

Shareholders Are Optimistic That Aier Eye Hospital Group (SZSE:300015) Will Multiply In Value

Aier Eye Hospital Group Co., Ltd. to Report First Half, 2024 Results on Aug 26, 2024

Aier Eye Hospital Group Co., Ltd.'s (SZSE:300015) Business Is Yet to Catch Up With Its Share Price

Dividend of CN¥0.15 announced

Aier Eye Hospital Group Co., Ltd. Announces Final Dividend of A Shares for 2023, Payable on 06 June 2024

Now 21% undervalued after recent price drop

Statutory Profit Doesn't Reflect How Good Aier Eye Hospital Group's (SZSE:300015) Earnings Are

Consensus EPS estimates fall by 10%

Aier Eye Hospital Group Co., Ltd. (SZSE:300015) Fell Short of Analyst Expectations: Here's What You Need To Know

Aier Eye Hospital Group Co., Ltd., Annual General Meeting, May 21, 2024

Price target decreased by 8.3% to CN¥21.32

Aier Eye Hospital Group Co., Ltd. Announces Profit Distribution Proposal for 2023

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Calculating The Intrinsic Value Of Aier Eye Hospital Group Co., Ltd. (SZSE:300015)

Aier Eye Hospital Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Many Would Be Envious Of Aier Eye Hospital Group's (SZSE:300015) Excellent Returns On Capital

Aier Eye Hospital Group Co., Ltd.'s (SZSE:300015) Shares May Have Run Too Fast Too Soon

Aier Eye Hospital Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Price target decreased by 8.5% to CN¥24.37

Aier Eye Hospital Group Co., Ltd. (SZSE:300015) announces an Equity Buyback for CNY 300 million worth of its shares.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 8.2% to CN¥27.91

Second quarter 2023 earnings: EPS misses analyst expectations

Aier Eye Hospital Group Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Less than half of directors are independent

Aier Eye Hospital Group Co., Ltd. Announces Cash Dividend, Payable 08 June 2023

Aier Eye Hospital Group Co., Ltd. (SZSE:300015) announces an Equity Buyback for CNY 500 million worth of its shares.

Full year 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.33 in FY 2021)

Aier Eye Hospital Group Co., Ltd. Announces Board Appointments

Less than half of directors are independent

Consensus forecasts updated

Now 24% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings: EPS exceeds analyst expectations

Now 21% undervalued

Aier Eye Hospital Group Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 11 July 2022

Aier Eye Hospital Group Co., Ltd. Approves Cash Dividend for 2021

Now 22% undervalued

Now 28% undervalued after recent price drop

Aier Eye Hospital Group Co., Ltd. Announces Profit Distribution Proposal for 2021

First quarter 2022 earnings: EPS misses analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Price target decreased to CN¥59.67

Investor sentiment deteriorated over the past week

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 2Q 2020)

Aier Eye Hospital Group Co., Ltd. Approves Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.02 in 1Q 2020)

Price target increased to CN¥92.13

Aier Eye Hospital Group Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥63.79